Advanced Search
ORIGINAL ARTICLE
Korean J Pediatr 2015 September;58(9) :347-353.
Published online 2015 September 15.       
The efficacy and safety of Montelukast sodium in the prevention of bronchopulmonary dysplasia
Sang Bum Kim1, Jang Hoon Lee1, Juyoung Lee2, Seung Han Shin2, Ho Sun Eun3, Soon Min Lee3, Jin A Sohn2, Han Suk Kim2, Byung Min Choi4, Min Soo Park3, Kook In Park3, Ran Namgung3, Moon Sung Park1
1Department of Pediatrics, Ajou University School of Medicine, Suwon, Korea
2Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea
3Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea
4Department of Pediatrics, Korea University Ansan Hospital, Ansan, Korea
Corresponding Author: Moon Sung Park ,Tel: +82-31-219-5165, Fax: +82-31-219-5169, Email: drparkms@ajou.ac.kr
Copyright © 2015 by The Korean Pediatric Society
ABSTRACT
Purpose: The purpose of this study was to evaluate the efficacy and safety of Montelukast sodium in the prevention of bronchopulmonarydysplasia (BPD).
Methods: The Interventional study was designed as a multicenter, prospective, and randomized trial, with open labeled and parallel-experimental groups, 66 infants were enrolled and allocated to either the case group (n=30) or the control group (n=36) based on gestational age (GA). Infants in the case group were given Montelukast sodium (Singulair) based on their body weight (BW). Zero week was defined as the start time of the study.
Results: The incidence of moderate to severe BPD was not different between the groups (case group: 13 of 30 [43.3%] vs. control group: 19 of 36 [52.8%], P=0.912). Additionally, secondary outcomes such as ventilation index, mean airway pressure and resort to systemic steroids were not significantly different. There were no serious adverse drug reactions in either group, and furthermore the rate of occurrence of mild drug related-events were not significantly different (case group: 10 of 42 [23.8%] vs. control group: 6 of 48 (15.8%), P=0.414).
Conclusion: Montelukast was not effective in reducing moderate or severe BPD. There were no significant adverse drug events associated with Montelukast treatment.
Keywords: Broncopulmonary dysplasia | Leukotriene antagonists | Montelukast | Pharmacokinetics | Premature infant
TOOLS
PDF Links  PDF Links
Full text via DOI  Full text via DOI
Download Citation  Download Citation
Supplementary Material  Supplementary Material
  E-Mail
Share:      
METRICS
1,249
View
36
Download
Chorioamnionitis: Is a major player in the development of bronchopulmonary dysplasia?  2017 July;60(7)
The effects of neonatal ventilator care or maternal chorioamnionitis on the development of bronchopulmonary dysplasia  2009 August;52(8)
Montelukast as an add-on therapy in bronchopulmonary dysplasia  2009 February;52(2)
The effects of early surfactant treatment and minimal ventilation on prevention of bronchopulmonary dysplasia in respiratory distress syndrome  2009 January;52(1)
Risk Factors and Outcome of Bronchopulmonary Dysplasia  1994 January;37(1)
Register for e-submission
Register here to access the e-submission system of Korean J Pediatr for authors and reviewers.
Manuscript Submission
To submit a manuscript, please visit the Korean J Pediatr e-submission management system at http://submit.kjp.or.kr, read the Instructions for Authors, and log into the Korean J Pediatr e-submission system. For assistance with manuscript submission, please contact: kjpped@gmail.com.
Free archive
Anyone may access any past or current articles without logging in.
Korean Pediatric Society Office
#1606, Seocho World Officetel, 19 Seoun-ro, Seocho-gu, Seoul 137-070, Korea
TEL : +82-2-3473-7305    FAX : +82-2-3473-7307   E-mail: kjpped@gmail.com
BrowseCurrent IssueFor Authors and ReviewersAbout
Copyright© The Korean Pediatric Society. All right reserved.